

Denoyer Bernard  
Form 3  
January 27, 2010

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |  |                                      |  |  |
|--|--|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person *                              |  | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol                     |  |
| Â Denoyer Bernard  |  | (Month/Day/Year)                     | CALLISTO PHARMACEUTICALS INC [CSLP]                                    |  |
| (Last)   | (First)  | (Middle)                             | 01/26/2010   |  |
| C/O CALLISTO PHARMACEUTICALS, INC., Â 420 LEXINGTON AVENUE, SUITE 1609 |  |                                      | 4. Relationship of Reporting Person(s) to Issuer                       | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| (Street)   |  |                                      |  | (Check all applicable)                               |
|  |  |                                      | <input type="checkbox"/> Director                                      | <input type="checkbox"/> 10% Owner                   |
|  |  |                                      | <input checked="" type="checkbox"/> Officer                            | <input type="checkbox"/> Other                       |
|  |  |                                      | (give title below)   | (specify below)                                      |
|  |  |                                      | Senior Vice President, Finance   |  |
| NEW YORK, Â NY Â 10170   | 6. Individual or Joint/Group Filing(Check Applicable Line) |                                      |  |  |
| (City)   | (State)  | (Zip)                                | <input checked="" type="checkbox"/> Form filed by One Reporting Person |  |
|  |  |                                      | <input type="checkbox"/> Form filed by More than One Reporting Person  |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|
|------------------------------------|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and Expiration Date<br>(Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|---|---|--|---|---|--|
|---|---|--|---|---|--|

## Edgar Filing: Denoyer Bernard - Form 3

|               | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) |   |
|---------------|------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|---|
| Stock Options | Â (1)            | 01/15/2014      | Common Stock | 100,000                    | \$ 3.6   | D                                     | Â |
| Stock Options | Â (2)            | 07/29/2015      | Common Stock | 75,000                     | \$ 1.38  | D                                     | Â |
| Stock Options | Â (3)            | 04/12/2017      | Common Stock | 75,000                     | \$ 0.66  | D                                     | Â |
| Stock Options | Â (4)            | 01/25/2020      | Common Stock | 75,000                     | \$ 0.26  | D                                     | Â |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                                  |       |
|---|---------------|-----------|----------------------------------|-------|
|   | Director      | 10% Owner | Officer                          | Other |
| Denoyer Bernard<br>C/O CALLISTO PHARMACEUTICALS, INC.<br>420 LEXINGTON AVENUE, SUITE 1609<br>NEW YORK, NY 10170 | Â             | Â         | Â Senior Vice President, Finance | Â     |

## Signatures

/s/ Bernard  
Denoyer

01/27/2010

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 50,000 options vested on each of 6/1/2005 and 6/1/2006.

(2) 25,000 options vested on each of 6/30/2006, 6/30/2007 and 6/30/2008

(3) 25,000 options vest on each of 4/12/2008, 4/12/2009 and 4/12/2010.

(4) 25,000 options vest on each of 1/25/2011, 1/25/2012 and 1/25/2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.